NK3 receptor antagonists move vasomotor symptom care beyond estrogen
Hot flashes and night sweats remain among the most disruptive symptoms in menopause and breast cancer survivorship, yet the standard treatment has long been out of reach for many patients. Menopausal hormone therapy is effective, but it is off the table for people with hormone-sensitive breast cancer and for others with contraindications such as cardiovascular risk or thromboembolic disease. The result has been a familiar clinical compromise: modest symptom relief from nonhormonal drugs that often bring their own adverse effects.
Neurokinin-3 receptor antagonists change that equation by acting on the hypothalamic circuitry that drives vasomotor instability, rather than replacing estrogen. The two approved agents in Canada, fezolinetant and elinzanetant, directly target the thermoregulatory pathway that becomes unstable in estrogen deficiency. In practical terms, they aim at the biology of the hot flash itself.
Why estrogen loss produces flushing, sweating, and sleep disruption
Estrogen deficiency narrows the thermoregulatory zone in the hypothalamus through hyperactivity of kisspeptin–neurokinin B–dynorphin neurons. When neurokinin B signaling rises, it activates NK3 receptors on both KNDy neurons and thermoregulatory neurons, and even small changes in core temperature can trigger flushing, sweating, and peripheral vasodilation. Substance P signaling through NK1 receptors adds another layer, contributing to vasodilation and disturbed sleep.
This pathway explains why a drug class built around NK3 antagonism is clinically attractive. Instead of suppressing symptoms indirectly, these agents interrupt the signaling loop that amplifies the menopausal hot flash. For patients whose breast cancer treatment depends on continued endocrine therapy, the appeal is obvious: symptom control without systemic estrogen exposure.
Trial evidence in menopause and breast cancer survivorship
The evidence base for this class now includes multiple randomized controlled trials in postmenopausal women with frequent hot flashes, generally defined as seven or more daily episodes. In one study of 527 participants, 175 received placebo, 176 received fezolinetant 30 mg, and 176 received fezolinetant 45 mg. At 12 weeks, both active doses reduced hot flash frequency more than placebo, with placebo-adjusted reductions of 2.39 and 2.55 fewer events per day, respectively, each with _p_ < 0.001.
A larger 52-week safety study enrolled 1,830 participants, including 610 on placebo, 611 on fezolinetant 30 mg, and 609 on fezolinetant 45 mg. Treatment-emergent adverse effects occurred in 64.1%, 67.9%, and 63.9% of participants, respectively, with no significant differences identified.
Elinzanetant has also shown benefit. In a trial of 400 participants, 200 received placebo and 200 received elinzanetant 120 mg daily. At 12 weeks, those taking elinzanetant had 3.2 fewer events per day than the placebo group, with a 95% confidence interval of 1.9 to 4.6 and _p_ < 0.001.
A second study is especially relevant for oncology practice. Among 474 women aged 18 to 70 years with moderate-to-severe vasomotor symptoms related to endocrine therapy for hormone-sensitive breast cancer or its prevention, 158 received placebo for 12 weeks followed by elinzanetant, while 316 received elinzanetant up front. At 12 weeks, vasomotor symptom frequency fell by 4.2 events per day in the placebo group and 7.8 events per day in the elinzanetant group, with _p_ < 0.001. Breast cancer-specific outcomes were not reported, and the effect of switching between NK receptor antagonists after inadequate response has not been studied.
The safety profile is reassuring, but not trivial
Short-term tolerability is generally favorable, yet the adverse-effect patterns differ enough to affect prescribing. With fezolinetant, abdominal pain, diarrhea, insomnia, and back pain have been reported. Elinzanetant is usually well tolerated, but central nervous system effects stand out: somnolence, fatigue, vertigo, dizziness, and presyncope occurred in 11.9% of elinzanetant-treated patients versus 3.5% with placebo.
Those symptoms fit the pharmacology. Because elinzanetant also blocks NK1 receptors, bedtime dosing is advised, and patients should avoid driving or hazardous activities until adverse effects settle. In a clinic setting, that counseling matters as much as the prescription itself.
Hepatic safety deserves special attention with fezolinetant. Transaminase elevations greater than three times the upper limit of normal occurred in about 2.3% of treated patients compared with 0.9% on placebo. Postmarketing cases of drug-induced liver injury with jaundice have also been reported. Health Canada recommends liver testing monthly for the first three months, then again at 6 and 9 months after treatment begins. Fezolinetant is contraindicated in cirrhosis, severe renal impairment, end-stage renal disease, and with CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin.
Elinzanetant has not shown the same hepatic concern in the available trials. Liver enzyme elevations occurred in 1.2% of treated participants and 1.0% of those on placebo, and the independent liver safety monitoring board did not identify a hepatotoxic signal. Routine serial liver monitoring is not recommended by Health Canada for this agent. Drug interactions still matter, though, because elinzanetant is metabolized by CYP3A4. Strong inhibitors such as ritonavir, cobicistat, itraconazole, and clarithromycin should be avoided, and the dose should be reduced to 60 mg daily with moderate inhibitors such as ciprofloxacin, fluconazole, verapamil, grapefruit juice, and other CYP3A4-inhibiting foods.
Why this class matters in breast cancer follow-up
Vasomotor symptoms are not a minor inconvenience for many patients taking endocrine therapy. They affect 78% to 93% of people receiving treatment for hormone-sensitive breast cancer and can contribute to treatment discontinuation rates exceeding 20%. For a population expected to remain on tamoxifen or aromatase inhibitors for 5 to 10 years after surgery, symptom burden can become a direct threat to adherence.
Earlier nonhormonal options, including SSRIs, SNRIs, gabapentin, clonidine, and oxybutynin, can help, but their effect is often partial and limited by side effects. In breast cancer populations, these approaches have reduced hot flash frequency by 38% to 58%, with placebo responses ranging from 15% to 50%. NK3 receptor antagonists offer a more targeted mechanism and, in the case of elinzanetant, phase III evidence directly in endocrine-therapy patients.
What remains unanswered in routine practice
Neither fezolinetant nor elinzanetant has yet shown an effect on bone mineral density or trabecular bone score, and their impact on cardiovascular or thromboembolic outcomes remains unmeasured. Frequent vasomotor symptoms have been associated with cardiovascular risk markers and bone loss, but causality is uncertain, and the long-term clinical meaning of symptom suppression alone is still unclear.
Cost, coverage, and long-term safety will determine how widely these drugs are used beyond early adopters. For now, they give clinicians a much-needed nonhormonal option for patients who cannot use estrogen, while leaving open the larger question of whether better symptom control will translate into better adherence, fewer interruptions in cancer therapy, and improved long-term outcomes.